Dexamethasone-YENPTY coupling compound, preparation method thereof and hydrogel preparation
The high level of existing dexamethasone eye drops in the treatment of eye inflammation is solved by coupling dexamethasone with YENPTY polypeptide sequence and combining with hydrogel to form a dexamethasone-YENPTY coupling compound hydrogel preparation. The problems of dose requirements and low penetration of eye tissues achieve efficient corneal penetration and controlled release of drugs, reducing the risk of side effects.
Patent Information
- Application Number
- CN202410824585.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-25
- Publication Date
- 2024-11-12
AI Technical Summary
The existing dexamethasone eye drops are insoluble in water when treating eye inflammation, which requires high dose infusion to prolong precorneal retention time, but this can cause side effects and the eye tissue penetration of eye drops is low. It is difficult to effectively suppress inflammation.
The coupling compound is formed by linking dexamethasone with clathrin-mediated endocytosis polypeptide sequence (YENPTY) through ester and amide bonds and combining it with a hydrogel preparation to form a dexamethasone-YENPTY coupled compound Hydrogel preparations are prepared by liquid phase synthesis and solid phase synthesis.
It realizes efficient corneal penetration of dexamethasone drugs and prolongs the anterior retention time, improves bioavailability, simplifies the preparation process, and controllable drug release, reducing the occurrence of side effects.
Smart Images

Figure CN118924911A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of biomedical materials, and in particular to a dexamethasone-YENPTY coupling compound and a preparation method and a hydrogel preparation thereof. Background Art
[0002] Dexamethasone is a glucocorticoid hormone with anti-inflammatory, anti-toxic and anti-allergic effects. Dexamethasone is insoluble in water, and its acetate or sodium phosphate salt prodrug is commonly used clinically, and its indications are wide, such as ocular inflammation caused by various reasons, including keratitis, scleritis, iritis, herpetic eye inflammation, sympathetic eye inflammation, cataract removal and postoperative endophthalmitis caused by implantation of artificial lens, glaucoma surgery, corneal transplantation surgery, myopia treatment surgery, etc. Clinically, whether it is dexamethasone sodium phosphate or tobramycin dexamethasone as eye drops, it is necessary to repeat local instillation to achieve sufficient therapeutic dose to inhibit inflammation, and the eye drops have low eye tissue penetration, so high-dose eye drops are required for treatment, but high doses often cause the generation of side effects. Therefore, the development of a new dexamethasone pharmaceutical preparation, after local instillation, can greatly prolong the corneal retention time and effectively achieve corneal penetration, thereby improving the bioavailability of dexamethasone drugs, has great clinical value.
[0003] The YENPTY polypeptide sequence is commonly found at the C-terminus of amyloid precursor protein and its family products. This polypeptide sequence is used for clathrin-mediated endocytosis signal recognition during the transmembrane transport of amyloid proteins and is also the binding site for many cytoplasmic adaptor proteins. Summary of the invention
[0004] In order to solve the deficiencies in the prior art, the present invention provides a dexamethasone-YENPTY coupling compound and a preparation method and a hydrogel preparation thereof.
[0005] The technical solution adopted by the present invention is: a dexamethasone-YENPTY coupling compound, wherein the dexamethasone-YENPTY coupling compound is formed by linking dexamethasone and a clathrin-mediated endocytosis polypeptide sequence (YENPTY) through an ester bond.
[0006] The dexamethasone-YENPTY coupling compound is formed by linking dexamethasone to succinic acid via an ester bond and then to a polypeptide sequence via an amide bond.
[0007] The clathrin-mediated endocytosis polypeptide sequence (YENPTY) is: tyrosine-glutamic acid-asparagine-proline-threonine-tyrosine.
[0008] The dexamethasone-YENPTY coupling compound has the following structural formula: .
[0009] The dexamethasone-YENPTY coupling compound is synthesized by combining a liquid phase synthesis method with a solid phase synthesis method.
[0010] A method for preparing a dexamethasone-YENPTY coupled compound comprises the following steps: (1) Preparation of dexamethasone ester: dexamethasone and succinic anhydride are dissolved in pyridine and reacted at room temperature overnight to obtain dexamethasone ester (dexamethasone-succinic acid); (2) Preparation of dexamethasone-YENPTY coupling compound: Place dichlororesin in a solid phase reactor, add dichloromethane to swell it, and then add tyrosine, threonine, proline, asparagine, glutamic acid, tyrosine, lysine and dexamethasone ester (dexamethasone-succinic acid) in sequence to extend the peptide chain until the final product, dexamethasone-YENPTY coupling compound, is obtained.
[0011] A dexamethasone-YENPTY coupling compound hydrogel preparation is prepared by the following steps: dissolving the dexamethasone-YENPTY coupling compound in a phosphate buffer solution, adding a weak alkaline aqueous solution, and standing to obtain a dexamethasone-YENPTY coupling compound hydrogel system.
[0012] The weight percentage of the dexamethasone-YENPTY coupling compound in the hydrogel preparation is 0.5% to 2%.
[0013] The pH value of the phosphate buffer solution is 7.4.
[0014] The weak base aqueous solution is a sodium carbonate aqueous solution.
[0015] The beneficial effects of the present invention are as follows: the present invention provides a dexamethasone-YENPTY coupled compound and a preparation method thereof and a hydrogel preparation; the dexamethasone-YENPTY coupled compound of the present invention is prepared by simple liquid phase synthesis and solid phase synthesis, with high yield and fast speed; the hydrogel preparation prepared from the dexamethasone-YENPTY coupled compound has the advantages of simple preparation, rapid gelation, precise and quantitative controllable drug loading, controllable drug release, etc. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Figure 1 It is the structural formula of dexamethasone-YENPTY conjugated compound.
[0017] Figure 2 This is the liquid chromatography-mass spectrometry spectrum of the dexamethasone-YENPTY coupling compound.
[0018] Figure 3 This is a transmission electron microscopy image of the dexamethasone-YENPTY conjugated compound.
[0019] Figure 4 Circular dichroism spectrum of dexamethasone-YENPTY conjugate. DETAILED DESCRIPTION
[0020] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0021] Example 1 Synthesis of Dexamethasone-YENPTY Conjugated Compounds: Dexamethasone (3.9 g, 10.0 mmol) and succinic anhydride (3.0 g, 30.0 mmol) were dissolved in pyridine (10 mL), and a magnetic stirrer was added to react overnight at room temperature. Appropriate amounts of pure water were added several times and rotary evaporated at 65 °C to produce a white suspension, which was filtered and the resulting white filter cake was dexamethasone ester (dexamethasone-succinic acid).
[0022] 1 g of dichlororesin (substitution degree 1-1.1 mmol) was placed in a solid phase reactor, 5 mL of dichloromethane was added to swell for 15 minutes, and 1.5 mmol of Fmoc-protected tyrosine (Y), 1.5 mmol of Fmoc-protected threonine (T), 1.5 mmol of Fmoc-protected proline (P), 1.5 mmol of Fmoc-protected asparagine (N), 1.5 mmol of Fmoc-protected glutamic acid (E), 1.5 mmol of Fmoc-protected tyrosine (Y), 1.5 mmol of Fmoc-protected lysine (K) and 3.0 mmol of dexamethasone ester were added in sequence, and the peptide chain was extended until the final product, dexamethasone-YENPTY coupling compound, was obtained. The HPLC-MS spectrum of the dexamethasone-YENPTY coupling compound is shown in FIG. Figure 2 As shown, the liquid phase image can also verify the purity of the product, and the mass spectrum can verify the molecular formula of the product.
[0023] Example 2: Using phosphate buffer solution as solvent, 0.5% wt dexamethasone-YENPTY coupled compound hydrogel was prepared: Accurately weigh 5 mg of dexamethasone-YENPTY and disperse it in 0.9 mL of phosphate buffer solution. Add 0.1 mL of sodium carbonate aqueous solution (1 equivalent to dexamethasone-YENPTY), dissolve it by ultrasonication, and let it stand to obtain a 0.5% wt dexamethasone-YENPTY hydrogel system.
[0024] Example 3 Using phosphate buffer solution as solvent, 1% wt dexamethasone-YENPTY hydrogel was prepared: Accurately weigh 10 mg of dexamethasone-YENPTY and disperse it in 0.9 mL of phosphate buffer solution. Add 0.1 mL of sodium carbonate aqueous solution (1 equivalent to dexamethasone-YENPTY), dissolve it by ultrasonication, and let it stand to obtain a 1% wt dexamethasone-YENPTY hydrogel system.
[0025] Example 4 Using phosphate buffer solution as solvent, 2% wt dexamethasone-YENPTY hydrogel was prepared: Accurately weigh 20 mg of dexamethasone-YENPTY and disperse it in 0.9 mL of phosphate buffer solution. Add 0.1 mL of sodium carbonate aqueous solution (1 equivalent to dexamethasone-YENPTY), dissolve it by ultrasonication, and let it stand to obtain a 2% wt dexamethasone-YENPTY hydrogel system.
[0026] The above are only preferred embodiments of the present invention, and the protection scope of the present invention is not limited to the above embodiments. All technical solutions under the concept of the present invention belong to the protection scope of the present invention. It should be pointed out that for ordinary technicians in this technical field, some improvements and modifications without departing from the principle of the present invention should be regarded as the protection scope of the present invention.
[0027] Technical personnel should note that although the present invention has been described according to the above specific implementation methods, the inventive concept of the present invention is not limited to this invention, and any modification using the inventive concept will be included in the scope of protection of this patent.
Claims
1. A dexamethasone-YENPTY coupling compound, characterized in that: The dexamethasone-YENPTY coupling compound is composed of dexamethasone and a clathrin-mediated endocytosis polypeptide sequence (YENPTY) linked by an ester bond.
2. The dexamethasone-YENPTY coupling compound according to claim 1, characterized in that: The dexamethasone-YENPTY coupling compound is formed by linking dexamethasone to succinic acid via an ester bond and then to a polypeptide sequence via an amide bond.
3. The dexamethasone-YENPTY coupling compound according to claim 1, characterized in that: The clathrin-mediated endocytosis polypeptide sequence (YENPTY) is: tyrosine-glutamic acid-asparagine-proline-threonine-tyrosine.
4. The dexamethasone-YENPTY coupling compound according to claim 3, characterized in that: The dexamethasone-YENPTY coupling compound has the following structural formula: 。 5. The dexamethasone-YENPTY coupling compound according to claim 1, characterized in that: The dexamethasone-YENPTY coupling compound is synthesized by combining a liquid phase synthesis method with a solid phase synthesis method.
6. A method for preparing the dexamethasone-YENPTY coupled compound according to claim 1, characterized in that: The following steps are involved: (1) Preparation of dexamethasone ester: dexamethasone and succinic anhydride are dissolved in pyridine and reacted overnight at room temperature to obtain dexamethasone-succinic acid; (2) Preparation of dexamethasone-YENPTY coupling compound: Place dichlororesin in a solid phase reactor, add dichloromethane to swell it, and then add tyrosine, threonine, proline, asparagine, glutamic acid, tyrosine, lysine and dexamethasone-succinic acid in sequence to extend the peptide chain until the final product, dexamethasone-YENPTY coupling compound, is obtained.
7. A hydrogel preparation of a dexamethasone-YENPTY coupled compound, characterized in that: The method is prepared by the following steps: dissolving the dexamethasone-YENPTY coupling compound in a phosphate buffer solution, adding a weak alkaline aqueous solution, and allowing the mixture to stand to obtain a dexamethasone-YENPTY coupling compound hydrogel system.
8. The hydrogel preparation according to claim 7, characterized in that The weight percentage of the dexamethasone-YENPTY coupling compound in the hydrogel preparation is 0.5% to 2%.
9. The hydrogel preparation according to claim 7, characterized in that The pH value of the phosphate buffer solution is 7.
4.
10. The hydrogel preparation according to claim 7, characterized in that The weak base aqueous solution is a sodium carbonate aqueous solution.
Citation Information
Cited By
Polypeptide-dexamethasone conjugate as well as preparation method and application thereof
CN119192407A
